__________________________________________________________________________________
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
__________________________________________________________________________________
FORM 6-K
__________________________________________________________________________________
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934
For the Month of December 2024
Commission File Number: 001-39777
__________________________________________________________________________________
NANOBIOTIX S.A.
(Translation of registrant’s name into English)
___________________________________________________________________________
60 rue de Wattignies 75012 Paris, France
(Address of principal executive offices)
__________________________________________________________________________________
INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K
On December 12, 2024, Nanobiotix SA (the “Registrant”) provided notification and public disclosure of transactions by persons discharging managerial responsibilities (“PDMR”) and persons closely associated with them in accordance with the requirements of the EU Market Abuse Regulation (“MAR”), which are attached hereto as Exhibit 99.1.
EXHIBIT INDEX
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
NANOBIOTIX S.A.
Date: December 12, 2024 By: Bart Van Rhijn Chief Financial Officer
